Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Rad's Clinical Dx Revenues Rise 18 Percent As Sales Improve Across the Board

NEW YORK (GenomeWeb News) — Bio-Rad Laboratories today said third-quarter revenues increased 11 percent as R&D spending rose 7 percent and profit jumped around 20 percent.
Total receipts for the three months ended Sept. 30 increased to $339.7 million from $304.8 million year over year.
Revenue from the company’s Clinical Diagnostics segment rose nearly 18 percent to $193.3 million as it experienced “strong growth across all product lines, particularly in quality control, auto-immune, diabetes, and blood virus testing products.”
Meantime, receipts from the Life Science division grew 4.1 percent to $143 million in part due to sales of its recently released ProteOn XPR36 protein interaction array system as well as the Bio-Plex suspension array systems and reagents.
R&D spending rose to $33.1 million from $31 million year over year.
Bio-Rad's profit jumped to $28 million from $23.2 million in the year-ago period.
Bio-Rad said it had around $472.8 million in cash and equivalents and $70.6 million in short-term investments as of Sept. 30.

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.